托西尼布磷酸盐|T7394|TargetMol

Toceranib Phosphate
874819-74-6

￥255 5mg 起订

￥417 10mg 起订

￥652 25mg 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 托西尼布磷酸盐

英文名称：: Toceranib Phosphate

CAS号：: 874819-74-6

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 98%

产品类别：: 抑制剂

货号：: T7394

Product Introduction

Bioactivity

名称	Toceranib Phosphate
描述	Toceranib Phosphate (SU11654 phosphate), is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including Flk-1/KDR, PDGFR
动物实验	Dogs scheduled to received toceranib phosphate treatment were divided into 2 groups based on SBP recorded at screening: dogs that were normotensive were assigned to Group 2a and dogs diagnosed with HT were assigned to Group 2b. After baseline evaluation, dogs enrolled in Group 2a received toceranib phosphate at a standard dose as previously published.2 Group 2b dogs received toceranib phosphate as described, but were also treated with standard‐of‐care treatment for HT, including amlodipine besylate (0.2–0.4 mg/kg PO q 24 hours), enalapril maleate (0.5 mg/kg PO q 12 hours), or both, initiated at the discretion of the attending veterinarian. Some dogs were treated with additional medications, including corticosteroids, at the discretion of the oncologist. All dogs were re‐evaluated on Day 14 (±3 days) at which time a UPC and blood pressure measurements were performed[1].
体内活性	在之前为正常血压的治疗犬开始使用toceranib phosphate治疗后，其收缩压显著（P = 0.0013）上升至152 mmHg ± 19，相较于基线水平136 mmHg ± 14有所增加。有37%的接受治疗的犬只发展为收缩压≥ 160 mmHg。治疗犬在开始治疗时，系统性高血压（37%）和蛋白尿（21%）的发生率与年龄相匹配的健康对照组（分别为15% [P = 0.13] 和0% [P = 0.069]）无显著差异。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : Slightly soluble
关键字	SU11654 \| inhibit \| SU11654 Phosphate \| SU-11654 \| Toceranib \| SU 11654 Phosphate \| VEGFR \| PHA 291639E \| Platelet-derived growth factor receptor \| PHA 291639 Phosphate \| PHA291639 Phosphate \| CD117 \| SU-11654 Phosphate \| Toceranib Phosphate \| Vascular endothelial growth factor receptor \| SU 11654 \| SCFR \| PHA-291639 Phosphate \| c-Kit \| Inhibitor \| PDGFR
相关产品	Oxyresveratrol \| Sorafenib
相关库	抑制剂库 \| 经典已知活性库 \| 抗癌上市药物库 \| 抗癌活性化合物库 \| 激酶抑制剂库 \| EMA 上市药物库 \| 膜蛋白靶向化合物库 \| 药物功能重定位化合物库 \| 抗癌药物库

SU11654 phosphate|||PHA 291639 phosphate|||托西尼布磷酸盐|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务